MRI

Latest News


CME Content


Physicians have used palpation regularly as a diagnostic technique since the days of the ancient Greeks. Up to now, the potential value of this method has been explored in the imaging field only by ultrasound research teams, but at this year’s ECR technical exhibition, delegates can see for themselves how the same principles may be combined with MRI to improve diagnosis in patients with liver disease.

The brains of 24 retired U.S. National Football League players with known cognitive impairment show signs of damaging atrophy, according to advanced MRI studies described at the 2009 RSNA annual meeting.

Recently, thousands of European radiologists have received an e-mail with this rather alarmist heading: “EU directive still threatens MRI.” Another e-mail doing the rounds has an equally sensational title: “No more MRI in Europe?”

Though generally deemed safe, high-intensity focused-ultrasound ablation of liver and pancreas cancers can lead to delayed complications. According to Korean researchers, practitioners should be aware of-and watch closely for-local and systemic post-HIFU side effects several years down the road.

Toshiba laid the groundwork for entering the 3T marketplace in the U.S. with the unveiling of its Vantage Titan 3T system at RSNA 2009. The work-in-progress, which is pending FDA clearance, leapfrogs earlier generations of 3T scanners with a 71-cm tapered aperture and Pianissimo noise reduction technology.

McKesson is showcasing its latest image management technology on the RSNA exhibit floor, a workflow enhancement called Variable Thickness Regional Intensity Projection (VTRIP), which promises more efficient reading of CT and MR studies.

MRI is the best method to assess breast cancer tumor size prior to surgery and after chemotherapy, according to findings from the American College of Radiology Imaging Network trial 6657. Size on mammography does not correlate with true residual disease in patients treated with neoadjuvant chemotherapy and thus MRI is the best modality, the researchers said.

CMC-001, an investigational MRI liver contrast medium, may be at least a partial answer to reducing the long imaging times that have frustrated patients and encouraged radiologists to look for imaging alternatives to aid diagnosis of hepatocellular carcinoma and colon cancer metastases in the liver. A phase III trial indicates it is as sensitive as a gadolinium-enhanced MRI for detecting colon cancer metastases, but at the cost of lower specificity.

Siemens brought two blockbuster MR offerings to the RSNA meeting this week: the 3T Skyra and 1.5T Aera. The two new products, works-in-progress pending FDA clearance but scheduled to begin shipping by mid-2010, promise a productivity lift through their patient-friendly bores, measuring 70 cm wide, and automation that simplifies complex scan tasks.